glp 1 agonist australia Updated guidance for patients using GLP-1/GIP receptor agonists Targeting GLP-1, GIP & GCG

doi:10.1007/s00125-008-1149-y Buteau J

For now, patients who are taking semaglutide or considering treatment should discuss the risks and benefits with their doctors, especially those who have other known optic nerve problems such as glaucoma or preexisting visual loss, experts say It is important to consult with ophthalmology if patients experience visual changes, Narang said

N Engl J Med 379(16):15291539

Simonen P, Gylling H, Howard AN, Miettinen TA

This stems from observations of thyroid C-cell hyperplasia in preclinical rodent studies

Writers advise that the ASA guidelines should strongly emphasize the current absence of sufficient evidence